Fast Facts for Board Review

Biologics for Psoriasis

Cutis. 2016 March;97(3)

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

PDF Download

 

3. Which biologic has been shown to worsen existing Crohn disease?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

Pages

Recommended Reading

Minimal disease activity criteria in PsA fall short
Psoriasis Collection
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis
Psoriasis Collection
Don’t overlook topical tazarotene for psoriasis
Psoriasis Collection
How to Manage Psoriasis Safely in Pregnant Women
Psoriasis Collection
Fresh evidence of methotrexate efficacy in psoriatic arthritis
Psoriasis Collection
Sparse, poor evidence supports fumarates for psoriasis
Psoriasis Collection
Atopic Dermatitis Treatments Moving Forward: Report From the AAD Meeting
Psoriasis Collection
Ixekizumab approved for plaque psoriasis
Psoriasis Collection
Ustekinumab Linked to More Outpatient Visits and Greater Pharmacy Costs Versus Adalimumab in Psoriasis Patients
Psoriasis Collection
Biologics for Pediatric Psoriasis Patients?
Psoriasis Collection

Related Articles

  • Article

    Allergic Contact Dermatitis, Part 4

    Author:
    Laura Doerfler, MD
    William W. Huang, MD, MPH

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Article

    Viruses, Part 2: RNA Viruses

    Author:
    Jenna O'Neill, MD

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Article

    Genetic Pathways, Part 2

    Author:
    Alyssa Daniel, MD
    Publish date: December 29, 2015

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...